• 1
    Chang JTC, Chan SC, Yen TC, et al. Nasopharyngeal carcinoma staging by F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2006; 62: 501-507.
  • 2
    King AD, MA BB, Yau YY, et al. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. Br J Radiol. 2008; 81: 291-298.
  • 3
    Liu FY, Chang JT, Wang HM, et al. [18F] Fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2006; 24: 599-604.
  • 4
    Liu FY, Lin CY, Chang JT, et al. 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med. 2007; 48: 1614-1619.
  • 5
    Chua MLK, Ong SC, Wee JTS, et al. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. Head Neck. 2009; 31: 346-354.
  • 6
    Ng SH, Chan SC, Yen TC, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging. 2009; 36: 12-22.
  • 7
    Yen TC, Lin CY, Wang HM, et al. 18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65: 1307-1314.
  • 8
    Chan SC, Yen TC, Ng SH, et al. Differential roles of 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management. J Nucl Med. 2006; 47: 1447-1454.
  • 9
    Yen TC, Chang JTC, Ng SH, et al. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med. 2005; 46: 405-410.
  • 10
    Chan SC, Ng SH, Chang JTC, et al. Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2006; 33: 1032-1040.
  • 11
    Comoretto M, Balestreri L, Borsatti E, et al. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT. Radiology. 2008; 249: 203-211.
  • 12
    Ng SH, Chang JTC, Chan SC, et al. Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med. 2004; 45: 1669-1676.
  • 13
    Yen RF, Hong RL, Tzen KY, et al. Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma. J Nucl Med. 2005; 46: 770-774.
  • 14
    Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350: 2461-2470.
  • 15
    Lo YMD, Chan LYS, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999; 59: 1188-1191.
  • 16
    Twu CW, Wang WY, Liang WM, et al. Comparison the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007; 67: 130-137.
  • 17
    Lo YMD, Chan ATC, Chan LYS, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000; 60: 6878-6881.
  • 18
    Chan ATC, Lo YMD, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002; 94: 1614-1619.
  • 19
    Leung SF, Chan ATC, Zee B, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of post-therapy distant failure in patients with early stage nasopharyngeal carcinoma of undifferentiated type. Cancer. 2003; 98: 288-291.
  • 20
    Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006; 24: 5414-5418.
  • 21
    Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008; 49: 480-508.
  • 22
    Makitie AA, Reis PP, Irish J, et al. Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study. Head Neck. 2004; 26: 815-822.